Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2018 Oct 31;13(10):e0206519. doi: 10.1371/journal.pone.0206519

Leptin gene variants and colorectal cancer risk: Sex-specific associations

Kelsey A Chun 1,*,#, Jonathan M Kocarnik 1,2,#, Sheetal S Hardikar 1,3, Jamaica R Robinson 1,2, Sonja I Berndt 4, Andrew T Chan 5, Jane C Figueiredo 6,7, Noralane M Lindor 8, Mingyang Song 5,9,10, Robert E Schoen 11, Richard B Hayes 12, John D Potter 1,13, Rami Nassir 14, Stéphane Bézieau 15, Loic Le Marchand 16, Martha L Slattery 17, Emily White 1,13, Ulrike Peters 1,13, Polly A Newcomb 1,13
Editor: Sergi Castellví-Bel18
PMCID: PMC6209341  PMID: 30379922

Abstract

Background

High levels of serum leptin and low levels of serum adiponectin are strongly correlated with obesity, a well-established risk factor for colorectal cancer (CRC). Growing evidence suggests that dysregulation of leptin and adiponectin levels may play an etiological role in colorectal carcinogenesis. We evaluated 20 candidate variants in 4 genes previously shown to alter serum leptin and adiponectin levels for associations with obesity (BMI>30 kg/m2) and CRC risk.

Methods

We analyzed 6,246 CRC cases and 7,714 population-based controls from 11 studies within the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). Associations of each variant with obesity or CRC were evaluated using multivariate logistic regression models stratified by sex and adjusted for age, a study variable, and the first three principal components of genetic ancestry. Gene-specific False Discovery Rate (FDR)-adjusted p-values <0.05 denoted statistical significance.

Results

Two variants in the leptin gene showed statistically significant associations with CRC among women: LEP rs2167270 (OR = 1.13, 95% CI: 1.06–1.21) and LEP rs4731426 (OR = 1.09, 95% CI: 1.02–1.17). These associations remained significant after adjustment for obesity, suggesting that leptin SNPs may influence CRC risk independent of obesity. We observed statistically significant interactions of the leptin variants with hormone replacement therapy (HRT) for CRC risk; these variant associations were strengthened when analyses were restricted to post-menopausal women with low estrogen exposure, as estimated by ‘never use’ of HRT and/or non-obese BMI. No variants were associated with CRC among men.

Conclusions

Leptin gene variants may exhibit sex-specific associations with CRC risk. Endogenous and exogenous estrogen exposure may modify the association between these variants, leptin levels, and CRC risk.

Introduction

Both high levels of serum leptin and low levels of serum adiponectin are strongly correlated with obesity [1, 2], which is a well-established risk factor for colorectal cancer (CRC) [3]. Whether there is a direct relationship between aberrant leptin and adiponectin levels and CRC independent of obesity, however, is not well characterized. Previous evidence suggests that leptin and adiponectin—two adipocyte-derived hormones that are involved in the regulation of energy homeostasis and insulin sensitivity [4]—may influence the colorectal carcinogenic pathway in opposing ways. Leptin has been shown to act as a growth factor in colonic epithelial cells, promoting tumor cell proliferation and migration and suppressing apoptosis [5]. Adiponectin, by contrast, has been shown to exert an anti-tumorgenic effect by inhibiting cancer cell growth and inducing apoptosis [6].

Epidemiological studies have yielded inconsistent findings on the relationship between adipokine levels and CRC. Several studies have found higher serum leptin [7, 8] and lower serum adiponectin [9–11] levels to be associated with elevated CRC risk, while other studies report conflicting [12–14] or null [15, 16] associations. In addition, several studies have reported that the relationship between adipokine levels and CRC varies by sex [17–21], with stronger positive associations reported in males. Genetic variation in the genes encoding these hormones, or their hormone receptors, may contribute to these differential associations. Greater insight into the role of leptin and adiponectin gene variants in colorectal carcinogenic pathways may therefore contribute to our understanding of the genetic basis of CRC risk.

This study investigated the potential role of candidate gene variants of leptin and adiponectin in sex-specific pathways of obesity and colorectal carcinogenesis. A literature search for variants reported to alter circulating leptin or adiponectin levels identified 20 variants in the genes encoding leptin, adiponectin, and their respective receptors. Associations between these variants with obesity and CRC risk were evaluated using the large data resources of the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) [22, 23].

Materials and methods

Variant selection

A literature search in the PubMed database identified studies that characterized the association between gene variants in leptin (LEP), leptin receptor (LEPR), adiponectin (ADIPOQ), or adiponectin receptor (ADIPOR1) and serum levels of leptin or adiponectin. Variants previously reported as significantly associated with serum leptin or adiponectin levels in at least one prior study were included in our analysis [24–38]. Variants reported as significant predictors of CRC in at least one prior study were included, regardless of whether the gene variants had also been linked to serum hormone levels [39–47]. In total, this literature search identified 20 variants across these four genes: 3 in LEP, 3 in LEPR, 11 in ADIPOQ, and 3 in ADIPOR1.

Study population

This analysis utilized 6,246 CRC cases (4,996 colon cancer, 1,108 rectal cancer) and 7,714 population-based controls pooled from 11 epidemiologic studies within GECCO. This included: the French Association Study Evaluating RISK for sporadic colorectal cancer (ASTERISK); Hawaii Colorectal Cancer Studies 2&3 (Colo2&3); Diet, Activity, and Lifestyle Study (DALS); Health Professionals Follow-up Study (HPFS); Multiethnic Cohort (MEC); Nurses’ Health Study (NHS); Physician's Health Study (PHS); Prostate, Lung, Colorectal Cancer, and Ovarian Cancer Screening Trial (PLCO); Postmenopausal Hormone Study (PMH); VITamins And Lifestyle (VITAL); and Women's Health Initiative (WHI). Study design and inclusion details regarding individual studies within GECCO have been previously described [22, 23]. Colorectal cancer cases were previously defined by GECCO via ICD-9 codes as stage 1–4 colorectal adenocarcinoma. Obesity was defined as body mass index (BMI) ≥ 30 kg/m2, consistent with the World Health Organization (WHO) definition [48].

Genotyping and imputation

We used existing genotype data from prior genome-wide association studies (GWAS) performed in GECCO, the details of which have been previously described [22, 23]. Briefly, genotyping and quality control were performed using a standard process that excluded variants that did not meet quality control measures for Hardy-Weinberg Equilibrium in controls (HWE p<10−4) or low call rate (<98%). To increase coverage, genotypes were imputed to the Haplotype Reference Consortium (version 1) [49], excluding variants that had a low minor allele count (MAC < 5) or poor imputation accuracy (R2 < 0.3).

Statistical analysis

For each candidate variant, we examined the association with obesity and CRC risk. We calculated odds ratios (ORs) and 95% confidence intervals (95% CI) using multivariate logistic regression, with models stratified by sex and adjusted for age, a study variable that accounts for genotyping platform, and the first three principal components of genetic ancestry [50]. Sensitivity analyses conducted for variant associations with CRC were additionally adjusted for obesity (obese/non-obese BMI). ORs refer to the risk per coded allele. Sex-stratified analyses were conducted based upon previous evidence of the sex-dependent nature of relationships between obesity and CRC risk [51], serum leptin and colorectal adenoma risk [17], and serum adiponectin and CRC risk [18].

To account for multiple comparisons, False Discovery Rate (FDR)-adjusted p-values were calculated for variants within sex and within each gene or receptor, with pFDR <0.05 considered statistically significant [52]. Wald tests evaluated potential gene-gene and gene-environment interactions. All statistical tests and p-values were two-sided. All analyses were performed using STATA version 14.0 (StataCorp, College Station, TX).

Ethics statement

This study was approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Results

Selected characteristics of the studies and participants included in our analysis are described in Tables 1 and S1. The mean age of study participants across 11 studies was 63.8 years old, and mean BMI was 26.9 kg/m2.

Table 1. Demographic and baseline characteristics of colorectal cancer cases and controls.

Cases
N = 6,246		 Controls
N = 7,714
Women
N = 3,591 (%)		 Men
N = 2,655 (%)		 Women
N = 4,643 (%)		 Men
N = 3,071 (%)
Age, years
    Under 50 112 (3) 172 (6) 275 (6) 226 (7)
    50–59 728 (20) 559 (21) 1,203 (26) 853 (28)
    60–69 1,635 (46) 1,106 (42) 2,150 (46) 1,272 (41)
    70–79 1,047 (29) 761 (29) 980 (21) 678 (22)
    80+ 69 (2) 57 (2) 35 (1) 42 (1)
BMI, kg/m2 [48]*
    Underweight, <18.5 31 (1) 7 (0) 55 (1) 8 (0)
    Normal, 18.5–24.9 1,192 (33) 654 (25) 1,855 (40) 979 (32)
    Overweight, 25.0–29.9 1,105 (31) 984 (37) 1,387 (30) 1,158 (38)
    Obese Class I, 30.0–34.9 561 (16) 330 (12) 584 (13) 287 (9)
    Obese Class II, 35.0–39.9 204 (6) 79 (3) 172 (4) 71 (2)
    Obese Class III, ≥ 40.0 112 (3) 30 (1) 92 (2) 11 (0)
Postmenopausal
    Yes 3,419 (95) — 4,246 (92) —
    No 151 (4) — 385 (8) —
HRT use at baseline* — —
    Yes 1,119 (31) — 1,870 (48) —
    No 1,916 (53) — 2,054 (52) —
EO HRT use at baseline* — —
    Yes 470 (13) — 941 (20) —
    No 1,680 (47) — 2,117 (46) —
Duration of EO HRT use* — —
    0 years (Never users) 211 (6) — 787 (17) —
    >10 years 446 (12) — 684 (15) —
    ≥10 years 270 (8) — 464 (10) —
Stage at Diagnosis*
    Stage 1 or local 1,127 (27) 800 (27) — —
    Stage 2/3 or regional 1,849 (45) 1,301 (44) — —
    Stage 4 or distant 420 (10) 274 (9) — —
Tumor Site* — —
    Colon 2,863 (80) 2,098 (79) — —
    Rectum 599 (17) 501 (19) — —
Open in a new tab

BMI = Body Mass Index; HRT = Hormone Replacement Therapy; EO = Estrogen-Only

*Do not sum to total due to missing values

Table 2 describes the candidate SNPs in leptin, adiponectin, and their receptors and summarizes their associations with CRC risk. Two variants in leptin were positively associated with CRC risk among women: LEP rs2167270 (OR = 1.13, 95% CI: 1.06–1.21, pFDR = 0.003) and LEP rs4731426 (OR = 1.09, 95% CI: 1.02–1.17, pFDR = 0.005). None of the 20 candidate variants, however, was statistically significantly associated with CRC risk among men. Testing the interaction between these variants and sex initially suggested a difference in CRC risk by sex for LEP variant rs4731426 (p = 0.06) but was not significant after FDR adjustment (pFDR = 0.18). Testing for variant associations under dominant or recessive genetic models did not substantially alter our results.

Table 2. Associations of candidate genetic variants with colorectal cancer.

Women Men
Gene Variant CA/RA CAF OR* (95% CI) p OR* (95% CI) p
LEP rs2167270 G/A 0.63 1.13 (1.06–1.21) <0.001+ 0.96 (0.89–1.04) 0.36
rs7799039 A/G 0.45 1.06 (0.99–1.13) 0.08 0.99 (0.92–1.07) 0.86
rs4731426 C/G 0.56 1.09 (1.02–1.17) 0.008+ 0.99 (0.92–1.07) 0.88
LEPR rs1137101 G/A 0.45 0.99 (0.92–1.05) 0.66 0.98 (0.91–1.06) 0.66
rs6588147 A/G 0.68 1.01 (0.94–1.08) 0.78 1.04 (0.96–1.13) 0.35
rs1137100 G/A 0.26 0.97 (0.90–1.04) 0.37 1.00 (0.91–1.09) 0.99
ADIPOR1 rs1342387 C/T 0.54 0.99 (0.93–1.06) 0.82 0.99 (0.91–1.06) 0.72
rs12733285 T/C 0.31 1.03 (0.96–1.11) 0.47 0.98 (0.90–1.07) 0.69
rs7539542 C/G 0.69 0.98 (0.91–1.06) 0.67 1.00 (0.92–1.09) 0.98
ADIPOQ rs1501299 T/G 0.28 0.96 (0.89–1.03) 0.23 1.00 (0.92–1.09) 0.95
rs17366743 C/T 0.03 1.00 (0.81–1.25) 0.96 1.05 (0.82–1.35) 0.70
rs16861194 G/A 0.08 0.99 (0.87–1.13) 0.90 0.95 (0.82–1.10) 0.47
rs2241766 C/T 0.11 0.97 (0.87–1.07) 0.55 1.01 (0.89–1.13) 0.93
rs17300539 T/C 0.09 0.86 (0.76–0.98) 0.03 0.99 (0.85–1.14) 0.85
rs822387 C/G 0.09 0.90 (0.79–1.02) 0.11 1.00 (0.86–1.15) 0.97
rs12495941 T/G 0.35 0.98 (0.91–1.05) 0.56 1.01 (0.93–1.10) 0.77
rs182052 A/G 0.34 0.98 (0.91–1.05) 0.51 0.96 (0.88–1.04) 0.35
rs822396 A/G 0.81 0.96 (0.88–1.04) 0.34 1.02 (0.92–1.12) 0.72
rs822395 A/C 0.65 1.00 (0.93–1.07) 0.94 1.03 (0.95–1.12) 0.47
rs1063538 C/T 0.61 1.06 (0.99–1.13) 0.10 1.00 (0.92–1.08) 0.95
Open in a new tab

CA = Coded Allele; RA = Reference Allele; CAF = Coded Allele Frequency; OR = Odds Ratio per coded allele; CI = Confidence Interval

* Adjusted for age, study, and first three principal components of genetic ancestry

+ p<0.05 after FDR-adjustment

The two leptin gene variants associated with CRC risk in women were not concomitantly associated with obesity (p = 1.00). To assess whether obesity was confounding the association between leptin variants and CRC in women, we adjusted our initial logistic regression model for obesity (obese/non-obese BMI). The associations of LEP variants rs2167270 and rs4731426 with CRC risk remained statistically significant after this adjustment (pFDR ≤ 0.03).

Based on prior studies of sex hormones in relation to leptin levels, as well as CRC risk, we performed stratified analyses according to exogenous estrogen exposure and assessed potential gene-environment interactions between the leptin variants and estrogen exposure with regards to CRC risk among women.

Among post-menopausal women, we observed that the associations of LEP rs2167270 and rs4731426 with CRC varied according to history of estrogen-only (EO) hormone replacement therapy (HRT) use, categorically defined as 0 years (Never users), <10 years, and ≥10 years (pFDR for interaction: 0.02 and 0.02, respectively). We then conducted stratified analyses in post-menopausal women according to history of EO HRT (Table 3). The associations of LEP rs2167270 and rs4731426 were non-significant in both categories of EO HRT ever users. In never users, however, the variants were statistically significantly associated with CRC risk, and their effect sizes were strengthened (LEP rs2167270: OR = 1.54, 95% CI: 1.19–1.99, pFDR = 0.003; LEP rs4731426: OR = 1.37, 95% CI: 1.08–1.74, pFDR = 0.03) (pFDR for interaction: 0.02 and 0.02, respectively).

Table 3. Associations of candidate leptin variants with colorectal cancer among post-menopausal women, by duration of estrogen-only hormone replacement therapy use.

≥10 years
(N = 696)		 <10 years
(N = 998)		 0 years
(N = 685)
Gene Variant OR* (95% CI) p OR* (95% CI) p OR* (95% CI) p
LEP rs2167270 0.97 (0.76–1.23) 0.79 1.06 (0.88–1.29) 0.53 1.54 (1.19–1.99) 0.001+
rs7799039 0.81 (0.65–1.02) 0.07 1.05 (0.88–1.26) 0.58 1.37 (1.08–1.74) 0.01+
rs4731426 0.96 (0.76–1.20) 0.70 1.01 (0.84–1.22) 0.89 1.37 (1.08–1.74) 0.01+
Open in a new tab

EO = Estrogen-Only; HRT = Hormone Replacement Therapy; OR = Odds Ratio per coded allele; CI = Confidence Interval

* Adjusted for age, study, and first three principal components of genetic ancestry

+ p<0.05 after FDR-adjustment

Given that the associations of leptin variants with CRC were strengthened when analyses were restricted to women with lower exogenous estrogen exposure, as estimated by never EO HRT use, we attempted to assess whether the trend would persist in women with lower endogenous estrogen exposure, using menopausal status and obesity status as proxies. Although no statistically significant interaction effects were observed between the two leptin gene variants and menopausal status or obesity status, in analyses stratified by menopausal status, associations of leptin variants with CRC risk remained statistically significant only among post-menopausal women. In analyses of post-menopausal women stratified by obese versus non-obese BMI, associations of the two leptin variants with CRC remained statistically significant in non-obese women only (Table 4). Among men and pre-menopausal women, analyses stratified by obese versus non-obese BMI did not yield any statistically significant SNP associations.

Table 4. Associations of candidate leptin variants with colorectal cancer among post-menopausal women, by obesity status.

Obese
(N = 1,599) 		Non-obese
(N = 4,886)
Gene Variant OR* (95% CI) p OR* (95% CI) p
LEP rs2167270 1.00 (0.86–1.16) 0.99 1.18 (1.08–1.29) <0.001+
rs7799039 0.97 (0.84–1.12) 0.69 1.06 (0.98–1.15) 0.15
rs4731426 0.96 (0.83–1.11) 0.60 1.13 (1.04–1.23) 0.003+
Open in a new tab

OR = Odds Ratio per coded allele; CI = Confidence Interval

* Adjusted for age, study, and first three principal components of genetic ancestry

+ p<0.05 after FDR-adjustment

Consistent with these observations, the CRC risk conferred by LEP variants rs2167270 and rs4731426 was highest among women who fulfilled all three categories of low estrogen exposure: non-obese, post-menopausal, never users of EO HRT (LEP rs2167270: OR = 1.69, 95% CI: 1.26–2.26, pFDR = 0.003; LEP rs4731426: OR = 1.49, 95% CI: 1.13–1.96, pFDR = 0.003). These results suggest that estrogen exposure–both exogenous and endogenous–may modify the association between leptin gene variants and CRC risk.

To examine whether other forms of HRT would have a similar impact on the association of leptin variants with CRC risk, we performed stratified analyses according to estrogen-progesterone (EP) HRT. Unlike with EO HRT use at baseline, associations of leptin variants with CRC risk were statistically significant among both users and non-users of EP HRT at baseline, and the association of both variants with CRC risk was only borderline significant among never users. Overall, EP HRT use did not appear modify SNP effects as strikingly as EO HRT use.

Given evidence in prior studies that obesity is more strongly associated with colon rather than rectal cancer [53], we assessed associations of SNPs with CRC in analyses stratified by subsite. However, no subsite-specific associations were statistically significant in analyses stratified by sex or across the total study population.

We also assessed potential gene-gene interactions between leptin and adiponectin variants with regards to CRC risk. Previous studies have posited that the ratio of circulating leptin to adiponectin levels may be a more salient marker of disease risk than leptin or adiponectin levels alone [19, 54]. Therefore, we hypothesized that the interaction of leptin and adiponectin variants might confer multiplicative CRC risk. However, modeling pairwise interactions between LEP and ADIPOQ variants for CRC risk did not identify any statistically significant interactions in sex-stratified analyses.

Although not the primary focus on our analyses, we also identified two variants significantly associated with obesity risk (S2 Table). As with the CRC associations, both associations with obesity were sex-specific. LEPR rs6588147 was associated with obesity among women (OR = 1.12, 95% CI: 1.03–1.22) but not among men. By contrast, ADIPOQ rs17366743 was associated with obesity among men (OR = 0.52, 95% CI: 0.34–0.79) but not among women.

Discussion

We found evidence for several sex-specific genetic associations with obesity and CRC risk. Two variants in the leptin gene (rs2167270 and rs4731426) were associated with increased CRC risk in women but not in men, and were not concomitantly associated with obesity. These associations remained statistically significant after adjustment for BMI, suggesting that these leptin variants may be associated with colorectal carcinogenesis independently of obesity.

Prior studies have reported associations of intronic variant rs4731426 and exonic variant rs2167270 with circulating leptin levels, suggesting that these SNPs are functional. Dasgupta et al. reported an increasing trend in leptin levels for each addition of the C minor allele in LEP rs4731426 [24]. Consistent with this finding, our study observed that the C allele of this variant was associated a modest increased risk of CRC among women.

Prior findings regarding LEP rs2167270 in relation to leptin levels and CRC risk have been conflicting. Some studies have observed associations of the A allele of LEP rs2167270 –the reference allele in our study–with elevated leptin levels [24, 55]. Contradictory to what we would then expect given the proposed directional effect, several studies have reported significant association of the A allele of this variant with decreased CRC risk [39, 40]. Consistent with these observations, our study observed that the G allele of this variant was associated with a modest increased CRC risk among women.

Linkage disequilibrium analysis of variants rs2167270 and rs4731426 revealed that the G allele and C allele of each variant, respectively, are highly correlated. We therefore matched the reference and coded alleles for LEP rs2167270 and rs4731426 to reflect this correlation. In our study, the correlation coefficient between coded alleles of leptin variants rs2167270 and rs4731426 was 0.85. Within NCI LDmatrix (https://analysistools.nci.nih.gov/LDlink/), the variants were found to have an r2 value of 0.72.

To our knowledge, ours is the first study to report sex-specific associations between leptin variants and CRC risk among women but not among men. Prior reports of sex differences in the association between adipokine levels and risk for colorectal neoplasia have found leptin and adiponectin levels to be more predictive of risk among men than among women [17–20]. Previously, Chia et al. reported a three-fold increased risk of colorectal adenoma for the highest versus lowest quartile of leptin among men, but found no association among women [17]. Yamaji et al. reported a 40% reduced risk of colorectal adenoma for the highest versus lowest tertile of adiponectin among men, but not among women [19]. Similarly, Song et al. reported a 45% lower risk of CRC for the highest versus lowest quartile of adiponectin among men, but no association among women [18]. Each of these studies’ analyses adjusted for important confounders, including BMI, waist circumference, or some other covariate associated with obesity, and found that their results remained statistically significant. The mechanisms underlying the heterogeneity by sex observed in these studies were unclear, though the authors proposed several hypotheses. One explanation was that sex differences in adipokine levels–in particular, higher levels of both adiponectin and leptin among women compared to men–contributed to the null finding in women [18]. Another explanation was that sex differences in body fat distribution may affect leptin levels and their observed effect on CRC risk [56].

Studies reporting sex differences in the associations between gene variants in leptin and adiponectin and CRC have been similarly limited to findings in men. A study by Partida-Perez et al. found that LEP rs2167270 was associated with CRC risk among men but not among women [57]. Slattery et al. reported a sex-specific association in leptin receptor, finding that LEPR rs6588147 was associated with increased risk of colon cancer among men but not among women [39].

Our finding on the relationship between leptin variants and CRC risk among women raises new questions regarding the mechanisms by which leptin and leptin gene variants might affect colorectal carcinogenic pathways. Given the interactions we observed between these variants and other factors, we propose mechanisms that may be independent of obesity.

We observed that associations of LEP rs2167270 and rs4731426 with CRC risk among women remained significant, and were strengthened, when analyses were restricted to women with low exogenous and endogenous estrogen exposure. The risk conferred by these leptin variants was highest among women who were post-menopausal, non-obese, and had no prior history of EO HRT use. These results suggest that estrogen exposure may modify the association between leptin gene variants and CRC risk. Specifically, estrogen exposure may be protective against the risk conferred by functional leptin variants, such that these variants only exert a detectable effect among women with low lifetime estrogen exposure. The mechanisms underlying this relationship in the context of our study remain unclear. However, prior studies have found suggestive evidence that sex-specific associations between leptin levels and CRC risk may involve functional cross-talk between leptin and estrogen systems [58].

Colorectal cancer incidence is lower among women compared with men, and it has been hypothesized that female hormones may play a protective role [59]. The protective effects of estrogen are believed to be mediated by ERβ –the predominant estrogen receptor in human colon [60]. ERβ expression is markedly and selectively reduced in CRC tissue compared to normal adjacent tissue [60], and inversely associated with stage of colorectal cancer and prognosis [61]. Silencing of ERβ by genetic knockdown or promoter methylation has been previously shown to induce aberrant cell proliferation while upregulation of ERβ has been shown to promote apoptotic signaling, suggestive of ERβ’s role as a tumor suppressor [62].

Leptin, by contrast, has been previously shown to act as a growth factor in colon epithelial cells. Binding of leptin to its receptor activates transcription (JAK/STAT) and Ras/extracellular signal-regulated kinase (ERK1/2) signal transduction pathways [63], inducing tumor cell proliferation and migration and suppressing apoptosis. Interestingly, evidence from prior studies suggests functional crosstalk between estrogen and leptin, with estrogen opposing the oncogenic effects of leptin. In adipocytes, estrogen (E2) administration has been shown to increase ERβ expression and subsequently reduce leptin expression [58]. In hepatic cells, E2 administration has been shown to inhibit leptin-stimulated cell growth (via decreased STAT3 signaling) and enhanced leptin-suppressed apoptosis (via increased SOCS3 signaling) through activation of ERβ [64]. These experimental findings support the results of our study, and taken together, suggest that estrogen exposure may be protective against the oncogenic effects of leptin variants associated with elevated circulating leptin levels.

In addition, that EO but not EP HRT use appeared to be strongly protective against leptin SNP-associated CRC risk in our study aligns with prior evidence for repression of estrogen-stimulated ER activity by liganded progestin receptor [65].

Our results may also shed light on a somewhat controversial hypothesis regarding obesity and CRC in post-menopausal women: that elevated endogenous estrogen in overweight and obese women–specifically postmenopausal women–may attenuate obesity-associated CRC risk [66, 67]. The relationship between obesity and CRC is known to be stronger in men compared in women, and when women are further stratified by menopausal status, the attenuated relationship between obesity and CRC risk is clearly restricted to postmenopausal women [68, 69]. Given the suggested protective effects of estrogen exposure among women and the fact that adipose tissue is the primary source of endogenous estrogen in postmenopausal women, it has been hypothesized that increased adiposity is less pathogenic in postmenopausal women than in their male and premenopausal counterparts. In our study, stratified analyses by obese versus non-obese BMI among postmenopausal women revealed that the CRC risk conferred by LEP SNPs was restricted to non-obese women. There was no evidence of leptin-associated CRC risk in the post-menopausal obese women, which may suggest that adiposity in postmenopausal women may confer some protective against the effects of leptin variants or elevated leptin levels.

A key strength of this study is its large sample size, leveraging nearly 14,000 CRC cases and controls pooled from 11 different studies. Although we selected variants that were functionally associated with protein expression, we nonetheless did not directly measure circulating leptin or adiponectin. In addition, our measures for estimating endogenous estrogen using menopausal status and obesity are only approximations. Despite the study’s limitations, we believe the results provide compelling suggestive evidence for the role of estrogen in modifying the carcinogenic effects of leptin. To our knowledge, this is the first study to report on estrogen as an effect modifier of leptin in an epidemiologic setting.

Validation studies evaluating our sex-specific genetic findings for CRC risk with directly measured serum levels of leptin, estrone, and estradiol would be very informative. Future studies should also be directed towards discerning the functional roles of these two leptin variants, which still remain largely unclear. Although candidate SNPs were selected for this study based on previously reported association with leptin levels, more direct laboratory investigation of these variants is still needed. To our knowledge, no experimental studies have adequately assessed the functional role of these variants beyond their correlation with leptin levels.

In conclusion, our study investigated the role of leptin and adiponectin in obesity and colorectal cancer using a candidate gene variant approach. Analyses revealed statistically significant sex-specific associations between two leptin gene variants–LEP rs2167270 and LEP rs4731426 –and CRC risk among women but not men. These gene variants in leptin were not associated with obesity risk among women and remained significantly associated with CRC after adjustment for obese vs non-obese BMI. In addition, these associations were strengthened when analyses were restricted to women with low estrogen exposure, as estimated by post-menopausal status, never use of hormone replacement therapy, and non-obese BMI. These results suggest that estrogen exposure may modify the association between leptin gene variants and CRC risk.

Supporting information

S1 Table. Characteristics of study participants across 11 studies in the Genetic Epidemiology of Colorectal Cancer Consortium (GECCO).

(DOCX)

Click here for additional data file. (13.3KB, docx)
S2 Table. Associations of candidate genetic variants with obesity.

(DOCX)

Click here for additional data file. (14.7KB, docx)

Acknowledgments

GECCO: The authors would like to thank all those at the GECCO Coordinating Center for helping bring together the data and people that made this project possible. The authors also acknowledge Deanna Stelling, Mark Thornquist, Greg Warnick, Carolyn Hutter, and team members at COMPASS (Comprehensive Center for the Advancement of Scientific Strategies) at the Fred Hutchinson Cancer Research Center for their work harmonizing the GECCO epidemiological data set. The authors acknowledge Dave Duggan and team members at TGEN (Translational Genomics Research Institute), the Broad Institute, and the Génome Québec Innovation Center for genotyping DNA samples of cases and controls, and for scientific input for GECCO.

ASTERISK: We are very grateful to Dr. Bruno Buecher without whom this project would not have existed. We also thank all those who agreed to participate in this study, including the patients and the healthy control persons, as well as all the physicians, technicians and students.

HPFS, NHS and PHS: We would like to acknowledge Patrice Soule and Hardeep Ranu of the Dana Farber Harvard Cancer Center High-Throughput Polymorphism Core who assisted in the genotyping for NHS, HPFS, and PHS under the supervision of Dr. Immaculata Devivo and Dr. David Hunter, Qin (Carolyn) Guo and Lixue Zhu who assisted in programming for NHS and HPFS, and Haiyan Zhang who assisted in programming for the PHS. We would like to thank the participants and staff of the Nurses' Health Study and the Health Professionals Follow-Up Study, for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.

PLCO: The authors thank Drs. Christine Berg and Philip Prorok, Division of Cancer Prevention, National Cancer Institute, the Screening Center investigators and staff or the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, Mr. Tom Riley and staff, Information Management Services, Inc., Ms. Barbara O’Brien and staff, Westat, Inc., and Drs. Bill Kopp and staff, SAIC-Frederick. Most importantly, we acknowledge the study participants for their contributions to making this study possible. The statements contained herein are solely those of the authors and do not represent or imply concurrence or endorsement by NCI.

PMH: The authors would like to thank the study participants and staff of the Hormones and Colon Cancer study.

WHI: The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: http://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Short%20List.pdf

Data Availability

The PLCO genetic data can be accessed with appropriate approval through the dbgap online resource (Prostate Cancer https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000207.v1.p1 and PanScan (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000206.v5.p3), accession numbers phs000207v.1p1 and phs000206.v3.p2, respectively. Lung cancer datasets are available at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000093.v2.p2, accession number phs000093.v2.p2. Data from the gecco studies are available from dbgap at the following accession number: phs001078.v1.p1.

Funding Statement

This work was supported by the National Institutes of Health (NIH) P30 CA015704; National Cancer Institute (NCI) 3 P30 CA015704-41S1; K05 CA152715 (PN); NCI KL2 TR000421 (JK); U01 CA137088 (UP); R01 CA059045 (UP).

References

  • 1.Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochemical and biophysical research communications. 2012;425(3):560–4. Epub 2012/08/29. 10.1016/j.bbrc.2012.08.024 . [DOI] [PubMed] [Google Scholar]
  • 2.Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. European journal of endocrinology. 2002;147(2):173–80. Epub 2002/08/03. . [DOI] [PubMed] [Google Scholar]
  • 3.Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2533–47. 10.1158/1055-9965.EPI-07-0708 . [DOI] [PubMed] [Google Scholar]
  • 4.Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes. 2004;53 Suppl 1:S143–51. Epub 2004/01/30. . [DOI] [PubMed] [Google Scholar]
  • 5.Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology. 2001;121(1):79–90. Epub 2001/07/05. . [DOI] [PubMed] [Google Scholar]
  • 6.Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Molecular endocrinology (Baltimore, Md). 2010;24(7):1441–52. Epub 2010/05/07. 10.1210/me.2009-0498 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Tamakoshi K, Toyoshima H, Wakai K, Kojima M, Suzuki K, Watanabe Y, et al. Leptin Is Associated with an Increased Female Colorectal Cancer Risk: A Nested Case-Control Study in Japan. Oncology. 2005;68(4–6):454–61. 10.1159/000086988 [DOI] [PubMed] [Google Scholar]
  • 8.Wang D, Gao L, Gong K, Chai Q, Wang G. Increased serum leptin level in overweight patients with colon carcinoma: A cross-sectional and prospective study. Molecular and clinical oncology. 2017;6(1):75–8. Epub 2017/01/27. 10.3892/mco.2016.1087 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. Journal of the National Cancer Institute. 2005;97(22):1688–94. Epub 2005/11/17. 10.1093/jnci/dji376 . [DOI] [PubMed] [Google Scholar]
  • 10.Gialamas SP, Petridou ET, Tseleni-Balafouta S, Spyridopoulos TN, Matsoukis IL, Kondi-Pafiti A, et al. Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism: clinical and experimental. 2011;60(11):1530–8. Epub 2011/06/03. 10.1016/j.metabol.2011.03.020 . [DOI] [PubMed] [Google Scholar]
  • 11.Tae CH, Kim SE, Jung SA, Joo YH, Shim KN, Jung HK, et al. Involvement of adiponectin in early stage of colorectal carcinogenesis. BMC cancer. 2014;14:811 Epub 2014/11/06. 10.1186/1471-2407-14-811 ; PubMed Central PMCID: PMCPMC4232655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Arpaci F, Yilmaz MI, Ozet A, Ayta H, Ozturk B, Komurcu S, et al. Low serum leptin level in colon cancer patients without significant weight loss. Tumori. 2002;88(2):147–9. Epub 2002/06/29. . [DOI] [PubMed] [Google Scholar]
  • 13.Joshi RK, Kim WJ, Lee S-A. Association between obesity-related adipokines and colorectal cancer: A case-control study and meta-analysis. World Journal of Gastroenterology: WJG. 2014;20(24):7941–9. 10.3748/wjg.v20.i24.7941 PubMed PMID: PMC4069321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. International journal of colorectal disease. 2009;24(3):275–81. Epub 2008/11/04. 10.1007/s00384-008-0605-y . [DOI] [PubMed] [Google Scholar]
  • 15.Lukanova A, Soderberg S, Kaaks R, Jellum E, Stattin P. Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(2):401–2. Epub 2006/02/24. 10.1158/1055-9965.EPI-05-0836 . [DOI] [PubMed] [Google Scholar]
  • 16.Aleksandrova K, Boeing H, Jenab M, Bueno-de-Mesquita HB, Jansen E, van Duijnhoven FJ, et al. Leptin and soluble leptin receptor in risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Cancer Res. 2012;72(20):5328–37. Epub 2012/08/29. 10.1158/0008-5472.CAN-12-0465 . [DOI] [PubMed] [Google Scholar]
  • 17.Chia VM, Newcomb PA, Lampe JW, White E, Mandelson MT, McTiernan A, et al. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2697–703. 10.1158/1055-9965.EPI-07-0467 . [DOI] [PubMed] [Google Scholar]
  • 18.Song M, Zhang X, Wu K, Ogino S, Fuchs CS, Giovannucci EL, et al. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study. Cancer Prev Res (Phila). 2013;6(9):875–85. Epub 2013/07/23. 10.1158/1940-6207.capr-13-0169 ; PubMed Central PMCID: PMCPMC3772620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Interaction between Adiponectin and Leptin Influences the Risk of Colorectal Adenoma. Cancer Research. 2010;70(13):5430 10.1158/0008-5472.CAN-10-0178 [DOI] [PubMed] [Google Scholar]
  • 20.Xu XT, Xu Q, Tong JL, Zhu MM, Huang ML, Ran ZH, et al. Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. Journal of digestive diseases. 2011;12(4):234–44. Epub 2011/07/28. 10.1111/j.1751-2980.2011.00504.x . [DOI] [PubMed] [Google Scholar]
  • 21.Stattin P, Palmqvist R, Soderberg S, Biessy C, Ardnor B, Hallmans G, et al. Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncology reports. 2003;10(6):2015–21. Epub 2003/10/10. . [PubMed] [Google Scholar]
  • 22.Peters U, Hutter CM, Hsu L, Schumacher FR, Conti DV, Carlson CS, et al. Meta-analysis of new genome-wide association studies of colorectal cancer risk. Human genetics. 2012;131(2):217–34. Epub 2011/07/16. 10.1007/s00439-011-1055-0 ; PubMed Central PMCID: PMCPMC3257356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, et al. Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology. 2013;144(4):799–807 e24. Epub 2012/12/26. 10.1053/j.gastro.2012.12.020 ; PubMed Central PMCID: PMC3636812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Dasgupta S, Salman M, Siddalingaiah LB, Lakshmi GL, Xaviour D, Sreenath J. Genetic variants in leptin: Determinants of obesity and leptin levels in South Indian population. Adipocyte. 2015;4(2):135–40. Epub 2015/07/15. 10.4161/21623945.2014.975538 ; PubMed Central PMCID: PMCPMC4496968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Hoffstedt J, Eriksson P, Mottagui-Tabar S, Arner P. A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2002;34(7):355–9. Epub 2002/08/22. 10.1055/s-2002-33466 . [DOI] [PubMed] [Google Scholar]
  • 26.Shahid A, Rana S, Mahmood S, Saeed S. Role of leptin G-2548A polymorphism in age- and gender-specific development of obesity. Journal of biosciences. 2015;40(3):521–30. Epub 2015/09/04. . [DOI] [PubMed] [Google Scholar]
  • 27.Li YX, Zhang Q, Shang XM, Li YQ, Liu XK, Liu CQ, et al. Association of two well-defined polymorphisms in leptin and leptin receptor genes with hypertension and circulating leptin: a meta-analysis. Archives of medical research. 2015;46(1):38–46. Epub 2014/12/06. 10.1016/j.arcmed.2014.11.012 . [DOI] [PubMed] [Google Scholar]
  • 28.Marginean CO, Marginean C, Voidazan S, Melit L, Crauciuc A, Duicu C, et al. Correlations Between Leptin Gene Polymorphisms 223 A/G, 1019 G/A, 492 G/C, 976 C/A, and Anthropometrical and Biochemical Parameters in Children With Obesity: A Prospective Case-Control Study in a Romanian Population-The Nutrichild Study. Medicine. 2016;95(12):e3115 Epub 2016/03/26. 10.1097/MD.0000000000003115 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Fan SH, Say YH. Leptin and leptin receptor gene polymorphisms and their association with plasma leptin levels and obesity in a multi-ethnic Malaysian suburban population. Journal of physiological anthropology. 2014;33:15 Epub 2014/06/21. 10.1186/1880-6805-33-15 ; PubMed Central PMCID: PMCPMC4073586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes. 2002;51(2):536–40. Epub 2002/01/29. . [DOI] [PubMed] [Google Scholar]
  • 31.Prakash J, Mittal B, Awasthi S, Srivastava N. Association of adiponectin gene polymorphism with adiponectin levels and risk for insulin resistance syndrome. International journal of preventive medicine. 2015;6:31 Epub 2015/05/08. 10.4103/2008-7802.154773 ; PubMed Central PMCID: PMCPMC4410438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Menzaghi C, Ercolino T, Di Paola R, Berg AH, Warram JH, Scherer PE, et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes. 2002;51(7):2306–12. Epub 2002/06/28. . [DOI] [PubMed] [Google Scholar]
  • 33.Guo X, Saad MF, Langefeld CD, Williams AH, Cui J, Taylor KD, et al. Genome-wide linkage of plasma adiponectin reveals a major locus on chromosome 3q distinct from the adiponectin structural gene: the IRAS family study. Diabetes. 2006;55(6):1723–30. Epub 2006/05/30. 10.2337/db05-0428 . [DOI] [PubMed] [Google Scholar]
  • 34.Roszkowska-Gancarz M, Bartoszewicz Z, Polosak J, Kurylowicz A, Jonas M, Mossakowska M, et al. Total and high molecular weight adiponectin and level-modifying polymorphisms of ADIPOQ in centenarians. Endokrynologia Polska. 2012;63(6):439–46. Epub 2013/01/23. . [PubMed] [Google Scholar]
  • 35.Tso AW, Sham PC, Wat NM, Xu A, Cheung BM, Rong R, et al. Polymorphisms of the gene encoding adiponectin and glycaemic outcome of Chinese subjects with impaired glucose tolerance: a 5-year follow-up study. Diabetologia. 2006;49(8):1806–15. Epub 2006/06/22. 10.1007/s00125-006-0324-2 . [DOI] [PubMed] [Google Scholar]
  • 36.Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Human molecular genetics. 2002;11(21):2607–14. 10.1093/hmg/11.21.2607 [DOI] [PubMed] [Google Scholar]
  • 37.Ong KL, Li M, Tso AW, Xu A, Cherny SS, Sham PC, et al. Association of genetic variants in the adiponectin gene with adiponectin level and hypertension in Hong Kong Chinese. European journal of endocrinology / European Federation of Endocrine Societies. 2010;163(2):251–7. Epub 2010/06/03. 10.1530/eje-10-0251 . [DOI] [PubMed] [Google Scholar]
  • 38.Laumen H, Saningong AD, Heid IM, Hess J, Herder C, Claussnitzer M, et al. Functional Characterization of Promoter Variants of the Adiponectin Gene Complemented by Epidemiological Data. Diabetes. 2009;58(4):984–91. 10.2337/db07-1646 PubMed PMID: PMC2661577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Slattery ML, Wolff RK, Herrick J, Caan BJ, Potter JD. Leptin and leptin receptor genotypes and colon cancer: gene-gene and gene-lifestyle interactions. International journal of cancer. 2008;122(7):1611–7. Epub 2007/12/07. 10.1002/ijc.23135 ; PubMed Central PMCID: PMCPMC2430084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Liu P, Shi H, Huang C, Shu H, Liu R, Yang Y, et al. Association of LEP A19G polymorphism with cancer risk: a systematic review and pooled analysis. Tumor Biology. 2014;35(8):8133–41. 10.1007/s13277-014-2088-5 [DOI] [PubMed] [Google Scholar]
  • 41.Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, et al. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. Jama. 2008;300(13):1523–31. Epub 2008/10/02. 10.1001/jama.300.13.1523 ; PubMed Central PMCID: PMCPMC2628475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Liu L, Zhong R, Wei S, Yin JY, Xiang H, Zou L, et al. Interactions between genetic variants in the adiponectin, adiponectin receptor 1 and environmental factors on the risk of colorectal cancer. PloS one. 2011;6(11):e27301 Epub 2011/11/17. 10.1371/journal.pone.0027301 ; PubMed Central PMCID: PMCPMC3210156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Guo X, Liu J, You L, Li G, Huang Y, Li Y. Association between adiponectin polymorphisms and the risk of colorectal cancer. Genetic testing and molecular biomarkers. 2015;19(1):9–13. Epub 2014/12/10. 10.1089/gtmb.2014.0238 ; PubMed Central PMCID: PMCPMC4278080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Hu X, Feng F, Li X, Yuan P, Luan R, Yan J, et al. Gene polymorphisms related to insulin resistance and gene-environment interaction in colorectal cancer risk. Annals of human biology. 2015;42(6):560–8. Epub 2015/07/24. 10.3109/03014460.2014.1002532 . [DOI] [PubMed] [Google Scholar]
  • 45.Al-Harithy RN, Al-Zahrani MH. The adiponectin gene, ADIPOQ, and genetic susceptibility to colon cancer. Oncology letters. 2012;3(1):176–80. Epub 2012/06/29. 10.3892/ol.2011.443 ; PubMed Central PMCID: PMCPMC3362502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Ye C, Wang J, Tan S, Zhang J, Li M, Sun P. Meta-analysis of adiponectin polymorphisms and colorectal cancer risk. International journal of medical sciences. 2013;10(9):1113–20. Epub 2013/07/23. 10.7150/ijms.6843 ; PubMed Central PMCID: PMCPMC3714387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Ye J, Jiang L, Wu C, Liu A, Mao S, Ge L. Three ADIPOR1 Polymorphisms and Cancer Risk: A Meta-Analysis of Case-Control Studies. PLOS ONE. 2015;10(6):e0127253 10.1371/journal.pone.0127253 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Organization WH. Obesity: preventing and managing the global epidemic: World Health Organization; 2000. [PubMed] [Google Scholar]
  • 49.the Haplotype Reference C, McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nature Genetics. 2016;48:1279 10.1038/ng.3643 https://www.nature.com/articles/ng.3643#supplementary-information. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904–9. 10.1038/ng1847 . [DOI] [PubMed] [Google Scholar]
  • 51.Calle EE, Thun MJ. Obesity and cancer. Oncogene. 2004;23(38):6365–78. Epub 2004/08/24. 10.1038/sj.onc.1207751 . [DOI] [PubMed] [Google Scholar]
  • 52.Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289–300. [Google Scholar]
  • 53.Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, et al. Obesity and Risk of Colorectal Cancer: A Systematic Review of Prospective Studies. PLOS ONE. 2013;8(1):e53916 10.1371/journal.pone.0053916 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Cleary MP, Ray A, Rogozina OP, Dogan S, Grossmann ME. Targeting the adiponectin:leptin ratio for postmenopausal breast cancer prevention. Frontiers in bioscience (Scholar edition). 2009;1:329–57. Epub 2009/06/02. . [DOI] [PubMed] [Google Scholar]
  • 55.Marcello MA, Calixto AR, de Almeida JF, Martins MB, Cunha LL, Cavalari CA, et al. Polymorphism in LEP and LEPR May Modify Leptin Levels and Represent Risk Factors for Thyroid Cancer. International journal of endocrinology. 2015;2015:173218 Epub 2015/03/27. 10.1155/2015/173218 ; PubMed Central PMCID: PMCPMC4355553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Baumgartner RN, Ross RR, Waters DL, Brooks WM, Morley JE, Montoya GD, et al. Serum leptin in elderly people: associations with sex hormones, insulin, and adipose tissue volumes. Obes Res. 1999;7(2):141–9. . [DOI] [PubMed] [Google Scholar]
  • 57.Partida-Perez M, de la Luz Ayala-Madrigal M, Peregrina-Sandoval J, Macias-Gomez N, Moreno-Ortiz J, Leal-Ugarte E, et al. Association of LEP and ADIPOQ common variants with colorectal cancer in Mexican patients. Cancer biomarkers: section A of Disease markers. 2010;7(3):117–21. Epub 2011/01/26. 10.3233/cbm-2010-0154 . [DOI] [PubMed] [Google Scholar]
  • 58.Yi Kyong W, Shin JH, Seo Hong S, Lee Jae K, Oh MJ, Kim T, et al. Role of Estrogen Receptor‐α and −β in Regulating Leptin Expression in 3T3‐L1 Adipocytes. Obesity. 2012;16(11):2393–9. 10.1038/oby.2008.389 [DOI] [PubMed] [Google Scholar]
  • 59.McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. Journal of the National Cancer Institute. 1980;65(6):1201–7. Epub 1980/12/01. . [PubMed] [Google Scholar]
  • 60.Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res. 2000;60(2):245–8. Epub 2000/02/10. . [PubMed] [Google Scholar]
  • 61.Rudolph A, Toth C, Hoffmeister M, Roth W, Herpel E, Jansen L, et al. Expression of oestrogen receptor β and prognosis of colorectal cancer. British journal of cancer. 2012;107(5):831–9. 10.1038/bjc.2012.323 PubMed PMID: PMC3425967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Williams C, DiLeo A, Niv Y, Gustafsson JA. Estrogen receptor beta as target for colorectal cancer prevention. Cancer letters. 2016;372(1):48–56. Epub 2015/12/29. 10.1016/j.canlet.2015.12.009 ; PubMed Central PMCID: PMCPMC4744541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell. 1995;83(7):1263–71. Epub 1995/12/29. . [DOI] [PubMed] [Google Scholar]
  • 64.Shen M, Shi H. Estradiol and Estrogen Receptor Agonists Oppose Oncogenic Actions of Leptin in HepG2 Cells. PLOS ONE. 2016;11(3):e0151455 10.1371/journal.pone.0151455 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Kraus WL, Weis KE, Katzenellenbogen BS. Determinants for the repression of estrogen receptor transcriptional activity by ligand-occupied progestin receptors. The Journal of steroid biochemistry and molecular biology. 1997;63(4–6):175–88. Epub 1998/02/12. . [DOI] [PubMed] [Google Scholar]
  • 66.Wang Y, Jacobs EJ, Teras LR, Pavluck AL, Rodriguez C, Thun MJ, et al. Lack of evidence for effect modification by estrogen of association between body mass index and colorectal cancer risk among postmenopausal women. Cancer causes & control: CCC. 2007;18(8):793–9. Epub 2007/07/10. 10.1007/s10552-007-9009-5 . [DOI] [PubMed] [Google Scholar]
  • 67.Hoffmeister M, Raum E, Winter J, Chang-Claude J, Brenner H. Hormone replacement therapy, body mass, and the risk of colorectal cancer among postmenopausal women from Germany. British journal of cancer. 2007;97(11):1486–92. Epub 2007/11/08. 10.1038/sj.bjc.6604066 ; PubMed Central PMCID: PMCPMC2360268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Adams KF, Leitzmann MF, Albanes D, Kipnis V, Mouw T, Hollenbeck A, et al. Body Mass and Colorectal Cancer Risk in the NIH–AARP Cohort. American Journal of Epidemiology. 2007;166(1):36–45. 10.1093/aje/kwm049 [DOI] [PubMed] [Google Scholar]
  • 69.Terry PD, Miller AB, Rohan TE. Obesity and colorectal cancer risk in women. Gut. 2002;51(2):191–4. PubMed PMID: PMC1773328. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Table. Characteristics of study participants across 11 studies in the Genetic Epidemiology of Colorectal Cancer Consortium (GECCO).

(DOCX)

Click here for additional data file. (13.3KB, docx)
S2 Table. Associations of candidate genetic variants with obesity.

(DOCX)

Click here for additional data file. (14.7KB, docx)

Data Availability Statement

The PLCO genetic data can be accessed with appropriate approval through the dbgap online resource (Prostate Cancer https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000207.v1.p1 and PanScan (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000206.v5.p3), accession numbers phs000207v.1p1 and phs000206.v3.p2, respectively. Lung cancer datasets are available at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000093.v2.p2, accession number phs000093.v2.p2. Data from the gecco studies are available from dbgap at the following accession number: phs001078.v1.p1.

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES